Uniqure N.V. (QURE)

Feb 20, 2025, 3:07 PM EST - 2 days ago

uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons

Feb 7, 2025, 1:04 PM EST - 15 days ago

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

Feb 7, 2025, 9:12 AM EST - 15 days ago

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Feb 3, 2025, 7:05 AM EST - 19 days ago

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

Jan 30, 2025, 7:37 AM EST - 23 days ago

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

Jan 8, 2025, 7:05 AM EST - 6 weeks ago

uniQure Announces Pricing of its Public Offering

Jan 7, 2025, 4:49 PM EST - 6 weeks ago

uniQure Announces Proposed Public Offering

Dec 30, 2024, 6:31 PM EST - 7 weeks ago

Final Trade: DVN, QURE, GOOGL, DFH

GOOG GOOGL DFH DVN

Dec 10, 2024, 7:05 AM EST - 2 months ago

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

Nov 21, 2024, 7:05 AM EST - 3 months ago

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Nov 5, 2024, 7:05 AM EST - 3 months ago

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Oct 15, 2024, 7:05 AM EDT - 4 months ago

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

Sep 23, 2024, 7:05 AM EDT - 5 months ago

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

Aug 15, 2024, 7:05 AM EDT - 6 months ago

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

Aug 6, 2024, 3:03 AM EDT - 7 months ago

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 1, 2024, 7:05 AM EDT - 7 months ago

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

Jul 23, 2024, 7:05 AM EDT - 7 months ago

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

Jul 12, 2024, 8:00 AM EDT - 8 months ago

What Led To A 150% Rise In UniQure Stock In A Week?

Jul 9, 2024, 1:48 PM EDT - 8 months ago

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

Jul 9, 2024, 7:05 AM EDT - 8 months ago

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease

Jul 1, 2024, 7:05 AM EDT - 8 months ago

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

Jul 1, 2024, 7:05 AM EDT - 8 months ago

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

Jun 3, 2024, 7:05 AM EDT - 9 months ago

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease

May 7, 2024, 7:05 AM EDT - 10 months ago

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

Feb 28, 2024, 7:05 AM EST - 1 year ago

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

Feb 1, 2024, 2:25 PM EST - 1 year ago

uniQure: The Valuation Got More Attractive

Dec 19, 2023, 7:05 AM EST - 1 year ago

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

Dec 11, 2023, 7:30 PM EST - 1 year ago

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Dec 8, 2023, 7:05 AM EST - 1 year ago

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 29, 2023, 7:05 AM EST - 1 year ago

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease

Nov 7, 2023, 7:05 AM EST - 1 year ago

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Oct 27, 2023, 10:00 AM EDT - 1 year ago

CSL and uniQure Win 2023 Prix Galien USA Award

Oct 24, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

Oct 5, 2023, 8:18 AM EDT - 1 year ago

UniQure to cut 28% of workforce and scrap more than half its research projects in strategic overhaul

Oct 5, 2023, 7:21 AM EDT - 1 year ago

Gene therapy maker UniQure to cut about 20% of workforce

Oct 5, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs

Sep 5, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

Aug 1, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Jun 26, 2023, 7:11 AM EDT - 1 year ago

uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

Jun 22, 2023, 8:45 AM EDT - 1 year ago

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm

Jun 21, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

Jun 20, 2023, 7:05 AM EDT - 1 year ago

uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy

Jun 20, 2023, 7:00 AM EDT - 1 year ago

CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B

May 22, 2023, 5:38 PM EDT - 1 year ago

Market Is Still Not Pricing In The FDA And EU EMA Approvals For uniQure

May 20, 2023, 9:19 AM EDT - 1 year ago

uniQure: Financials And Pipeline Signal A Promising Outlook For Investors

May 15, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million

May 9, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress